BR112017004429A2 - anticorpo monoclonal humanizado, que inibe a atividade enzimática da lipase endotelial vascular - Google Patents

anticorpo monoclonal humanizado, que inibe a atividade enzimática da lipase endotelial vascular

Info

Publication number
BR112017004429A2
BR112017004429A2 BR112017004429-3A BR112017004429A BR112017004429A2 BR 112017004429 A2 BR112017004429 A2 BR 112017004429A2 BR 112017004429 A BR112017004429 A BR 112017004429A BR 112017004429 A2 BR112017004429 A2 BR 112017004429A2
Authority
BR
Brazil
Prior art keywords
monoclonal antibody
lipase
hominization
checks
enzyme activity
Prior art date
Application number
BR112017004429-3A
Other languages
English (en)
Japanese (ja)
Inventor
Naito Shoichi
Aino Hiroaki
Nakamura Etsuo
Imai Sunao
Yamane Shoji
Original Assignee
Shionogi & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55459146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017004429(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co., Ltd. filed Critical Shionogi & Co., Ltd.
Publication of BR112017004429A2 publication Critical patent/BR112017004429A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a um anticorpo monoclonal humanizado ou um fragmento de anticorpo do mesmo que inibe seletivamente a atividade enzimática da lipase endotelial vascular e composições farmacêuticas contendo o mesmo como um ingrediente ativo útil para o tratamento de arteriosclerose ou síndrome metabólica.
BR112017004429-3A 2014-09-11 2015-09-10 anticorpo monoclonal humanizado, que inibe a atividade enzimática da lipase endotelial vascular BR112017004429A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014-184710 2014-09-11
JP2014184710 2014-09-11
PCT/JP2015/075668 WO2016039402A1 (ja) 2014-09-11 2015-09-10 血管内皮リパーゼの酵素活性を阻害するヒト化モノクローナル抗体

Publications (1)

Publication Number Publication Date
BR112017004429A2 true BR112017004429A2 (pt) 2018-02-27

Family

ID=55459146

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004429-3A BR112017004429A2 (pt) 2014-09-11 2015-09-10 anticorpo monoclonal humanizado, que inibe a atividade enzimática da lipase endotelial vascular

Country Status (19)

Country Link
US (2) US10570215B2 (pt)
EP (1) EP3192813A4 (pt)
JP (2) JP6635599B2 (pt)
KR (1) KR102520286B1 (pt)
CN (1) CN107074963B (pt)
AR (1) AR101811A1 (pt)
AU (1) AU2015313179B2 (pt)
BR (1) BR112017004429A2 (pt)
CA (1) CA2960994A1 (pt)
CL (1) CL2017000595A1 (pt)
EA (1) EA036324B1 (pt)
IL (1) IL250981B (pt)
MX (1) MX2017002968A (pt)
MY (1) MY181835A (pt)
PH (1) PH12017500461A1 (pt)
SG (2) SG10201900605SA (pt)
TW (2) TWI688575B (pt)
WO (1) WO2016039402A1 (pt)
ZA (1) ZA201702489B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351269B2 (en) * 2015-06-30 2022-06-07 Seagen Inc. Anti-NTB-A antibodies and related compositions and methods
US11623954B2 (en) * 2017-07-10 2023-04-11 Innate Pharma Siglec-9-neutralizing antibodies
EP3712170A4 (en) * 2017-11-10 2022-03-02 Jiangsu Hengrui Medicine Co., Ltd. CD96 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
CA3192235A1 (en) * 2019-11-07 2021-05-14 Medimmune, Llc Endothelial lipase antibodies for the treatment of cardiovascular diseases
CA3211692A1 (en) * 2020-02-24 2023-09-02 Medimmune, Llc Formulations of anti-endothelial lipase antibodies
WO2022095934A1 (zh) * 2020-11-05 2022-05-12 上海津曼特生物科技有限公司 抗Siglec-15抗体及其在制备药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH062075B2 (ja) * 1988-04-30 1994-01-12 大日本製薬株式会社 抗ヒトポストヘパリンプラズマ由来リポ蛋白リパーゼモノクローナル抗体およびその製造方法
IL129986A0 (en) * 1996-12-06 2000-02-29 Rhone Poulenc Rorer Pharma Polypeptides encoded by a human lipase-like gene compositions and methods
WO1999032611A1 (en) 1997-12-19 1999-07-01 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use
CA2363486C (en) 1999-03-26 2012-12-18 Michael Jaye Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol
JP6195306B2 (ja) * 2011-10-12 2017-09-13 塩野義製薬株式会社 Ｅｌの酵素活性を阻害するｅｌに対するモノクローナル抗体
JP6304775B2 (ja) * 2013-03-14 2018-04-04 塩野義製薬株式会社 血管内皮リパーゼの酵素活性を阻害するモノクローナル抗体

Also Published As

Publication number Publication date
EA201790590A1 (ru) 2017-08-31
SG11201701762VA (en) 2017-04-27
KR20170052655A (ko) 2017-05-12
US11136411B2 (en) 2021-10-05
MX2017002968A (es) 2017-06-15
TW202026313A (zh) 2020-07-16
JP6827255B2 (ja) 2021-02-10
KR102520286B1 (ko) 2023-04-10
EA036324B1 (ru) 2020-10-27
US20170260290A1 (en) 2017-09-14
IL250981A0 (en) 2017-04-30
EP3192813A4 (en) 2018-08-01
CL2017000595A1 (es) 2017-11-03
AU2015313179B2 (en) 2020-10-22
MY181835A (en) 2021-01-08
AR101811A1 (es) 2017-01-11
PH12017500461A1 (en) 2017-07-31
SG10201900605SA (en) 2019-02-27
US20200071424A1 (en) 2020-03-05
WO2016039402A1 (ja) 2016-03-17
JP6635599B2 (ja) 2020-01-29
JPWO2016039402A1 (ja) 2017-06-22
JP2020059743A (ja) 2020-04-16
CN107074963A (zh) 2017-08-18
CA2960994A1 (en) 2016-03-17
AU2015313179A1 (en) 2017-03-30
TWI688575B (zh) 2020-03-21
TW201613982A (en) 2016-04-16
TWI734410B (zh) 2021-07-21
US10570215B2 (en) 2020-02-25
EP3192813A1 (en) 2017-07-19
CN107074963B (zh) 2021-07-16
IL250981B (en) 2020-06-30
ZA201702489B (en) 2018-08-29

Similar Documents

Publication Publication Date Title
BR112017004429A2 (pt) anticorpo monoclonal humanizado, que inibe a atividade enzimática da lipase endotelial vascular
CL2019000979A1 (es) Composiciones y anticuerpos anti-lag-3.
BR112017021021A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112017017286A2 (pt) protease de cisteína
BR112017017284A2 (pt) protease de cisteína
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
BR112017017727A8 (pt) Heterociclos bicíclicos como inibidores de fgfr4
BR112018006257A2 (pt) anticorpos anti-pd-1 e composições
BR112017014341A2 (pt) método e sistema para tratamento, estabilização, ou redução da gravidade ou progressão de uma doença de fígado gorduroso não alcoólica, e, composição.
BR112015032595A2 (pt) inibidores de ido
BR112018013522A2 (pt) compostos inibidores de metaloenzima
BR112017003334A8 (pt) Variantes de desintegrina e usos farmacêuticos destas
BR112018015924A2 (pt) composições e métodos para tratar infecções
BR112018016004A2 (pt) composições e métodos para tratar feridas crônicas
EA201600012A1 (ru) Способ профилактики и/или лечения сердечно-сосудистых заболеваний
BR112015022009A2 (pt) Anticorpo monoclonal, inibindo a atividade enzimática de lipase endotelial vascular
AR102168A1 (es) Determinar petrofacies no lineales utilizando división de gráfica de interrelación
BR112016028948A2 (pt) ?composição bifásica?
BR112017005134A2 (pt) tratamento e cura funcional de infecção por hiv por anticorpos monoclonais para inibição de entrada de hiv competitiva mediada por cd
BR112016030599A8 (pt) novos derivados de aminoalquilbenzotiazepina e suas utilizações
TH167869A (th) สารยับยั้ง ido
EA201301341A1 (ru) Фармацевтическая композиция, обладающая панкреопротекторным действием, её применение для профилактики или лечения панкреатита и способ профилактики и лечения панкреатита

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]